BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join
back to Directory

Eigengene

Eigengene logo

Website
http://eigengene.com
Founded
2016

Technologies

AI Companies (Drug Discovery)

Eigengene develops proprietary AI, and uses it to analyze cancer whole genome sequencing (WGS) data, in order to develop (i) personalized prognostics and diagnostics, and (ii) novel therapeutics.

Our algorithms do what no others can, namely, simultaneously find both the similarities and dissimilarities across multiple and diverse high-dimensional datasets, known as tensors. This enables them to find what other methods miss. For example, in cancer genomic data, our algorithms were able to identify multi-hundred-thousand marker DNA signatures that predict a patient’s survival and response to treatment. Our algorithms can scale to petabyte-sized datasets, yet are sensitive enough to detect meaningful patterns in cohorts of as few as 250 patients, each with a genomic profile of billions of nucleotides. This enables us to tap the full wealth of information that sequencing the whole genome provides. Most other methods have difficulty finding patterns in such “skinny” datasets, in which the number of measured attributes per patient is far greater than the number of patients. However, they are the norm in cancer genomics.

We analyze DNA copy-number profiles, which can be measured far more reliably than the more usually used RNA expression. The fact that our signatures comprise hundreds of thousands of markers makes them robust to measurement errors. Our signatures predict novel drug targets that correlate with patients’ outcome. The discoveries that the algorithms make come directly from the genomic data and are not biased by the clinical information. The algorithms can use data from any and all platforms, including those that are already FDA approved and deployed in pathology labs.

#startups #AI #drugdiscovery

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

 

R&D Platform

Eigengene networks can be effective and biologically meaningful tools for studying the relationships between modules of a gene co-expression network. The proposed methods may reveal a higher order organization of the transcriptome.

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.